By using state-of-the-art genomic technologies and an unprecedented level of collaboration with the leading research institutions in New York, the NYGC is on the cutting edge of investigation into the origins, diagnosis and evolution of cancer.
Our Genome Center Cancer Group (GCCG), led by Harold Varmus, MD, NYGC and Weill Cornell Medicine, and Charles Sawyers, MD, Memorial Sloan Kettering Cancer Center, is composed of clinicians and cancer researchers from NYGC’s member institutions, including seven NCI-Designated Cancer Centers. The GCCG recently launched Polyethnic-1000, a project to study cancer in New York’s ethnically diverse, underserved patient populations. It is also spearheading the multi-institutional Very Rare Cancer Consortium, a research cohort focused on understanding the genetic causes for rare, understudied cancers.
Our Computational Cancer Genomics Working Group, led by Simon Tavaré, PhD, NYGC and Columbia University, and Sohrab Shah, PhD of Memorial Sloan Kettering Cancer Center, is building collaborations that apply novel statistical approaches and population-level analyses to major cohorts in cancer genomics.
NYGC Core Faculty Members Marcin Imielinski, MD, PhD; Dan Landau, MD, PhD; and Neville Sanjana, PhD, are all also engaged in pioneering cancer research.